Answers are grounded in this paper and cite their sources.
IgE cross-linking suggesting a role in mediating inflammation. We sought to determine the effects of ET523, a drug that reduces IgE-mediated cellular activation, on basophil function and TNF- secretion in IBD. Anti-IgE cross-linking induced basophil activation and cytokine secretion from cells from Crohn's disease and ulcerative colitis patients. Cells treated with ET523 reduced anti-IgE mediated cellular activation and TNF- secretion. Importantly, ET523 reduced unstimulated, basal secretion of TNF- in IBD. IgE-mediated cellular activation may play a role in systemic TNF- production in IBD. ET523 appears effective at reducing TNF- secretion and thus represents a novel agent to treat IBD.
No takes yet. Share an insight, caveat, or question.
BA et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: